About Xema
Xema Co., Ltd. is the only company in Russia which uses its own reagents for manufacturing of most ELISA kits we offer. This advantage allows us not only to be independent on external sources, but also to sell our reagents to other ELISA producers both in Russia (ZAO “Vector-Best”, NPO “DS”) and abroad – in Ukraine (“Granum” company), Italy (“Globe Diagnostic Srl.”), Israel (“Orgenics”), etc. Besides, our reagents are used worldwide in manufacturing rapid tests and for research purposes. Reagent manufacturing facilities include our vivarium in Balashikha and biochemical laboratories in Moscow and Saint-Petersburg used for purification of antigens and antibodies. These laboratories are also used for hybridoma production, growth of tumor cell lines and other in vitro manipulations. All our reagents are subjected to extensive quality control procedures to control purity, activity, specificity, etc., the obtained results being printed in the Certificate of Analysis issued for each lot. Quality of our reagents is supported by many scientific publications. That is why we successfully sell our reagents not only in Russia, but throughout the world, our main distributors for more than 10 years being such renowned companies as Hytest Oy (Turku, Finland) and Fitzgerald Industries International.
- Focus : Manufacturer
- Industry : Biotechnology
Product portfolio of Xema
Here you will find Xema-Medica Co. Ltd
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous